Astrazeneca: 2025 revenues +8% to $58.7 billion, earnings per share +11%
Profits driven by oncology and rare diseases, among others
In FY2025, Astrazeneca posted total revenues up 8% to $58.739bn, driven by the oncology and rare diseases segments, among others. Core eps (earnings per share) increased 11% to $9.16. For 2026, AstraZeneca expects continued sales growth, following a solid performance in its therapeutic areas and a strong product pipeline in 2025. Specifically, the UK pharmaceutical company said it expects sales growth in 2026, at constant exchange rates, of a mid-to-high single-digit percentage, and an increase in core earnings per share of a double-digit percentage.
For Pascal Soriot, Chief Executive Officer of AstraZeneca, 'in 2025, we had a strong commercial performance in all our therapeutic areas and excellent pipeline execution. We announced the results of 16 positive phase 3 studies during the year and now have 16 highly successful drugs. The momentum across our company continues into 2026 and we look forward to the results of more than 20 phase 3 studies this year. We have more than 100 ongoing phase 3 studies, including a substantial and growing number of studies of our transformative technologies that have the potential to revolutionise patient outcomes and drive our growth well beyond 2030. Finally, our company's ordinary shares began trading on the New York Stock Exchange on 2 February, resulting in a harmonised listing structure between the London, New York and Stockholm exchanges, allowing more shareholders to participate in our company's exciting future."
